Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, and 9 represent common stock, $0.001 par value per share ("Common Stock") of Forte Biosciences, Inc. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separate managed accounts. See Item 2 for more information. (2) The figures in Items 6, 8, and 9 include 141,224 shares of Common Stock that may be acquired by the Reporting Persons within 60 days pursuant to warrants held by the Reporting Persons, the exercise of which are subject to certain restrictions on the ability of the Reporting Persons to convert such warrants if, upon such conversion, the number of shares of Common Stock then beneficially owned by the Reporting Persons would exceed 4.99% of the outstanding shares of Common Stock. (3) The figure in Item 11 is based upon 12,353,341 shares of Common Stock outstanding, which includes the 141,224 shares of Common Stock that may be acquired by the Reporting Persons pursuant to warrants and the 12,212,117 shares of Common Stock of the Issuer outstanding at the closing of the registered offering of 5,630,450 shares of Common Stock of the Issuer on June 26, 2025, as disclosed in the Prospectus Supplement filed with the U.S. Securities and Exchange Commission (the "SEC") on June 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, and 9 represent Common Stock of the Issuer held by the Fund and certain separate managed accounts. See Item 2 for more information. (2) The figures in Items 6, 8, and 9 include 141,224 shares of Common Stock that may be acquired by the Reporting Persons within 60 days pursuant to warrants held by the Reporting Persons, the exercise of which are subject to certain restrictions on the ability of the Reporting Persons to convert such warrants if, upon such conversion, the number of shares of Common Stock then beneficially owned by the Reporting Persons would exceed 4.99% of the outstanding shares of Common Stock. (3) The figure in Item 11 is based upon 12,353,341 shares of Common Stock outstanding, which includes the 141,224 shares of Common Stock that may be acquired by the Reporting Persons pursuant to warrants and the 12,212,117 shares of Common Stock of the Issuer outstanding at the closing of the registered offering of 5,630,450 shares of Common Stock of the Issuer on June 26, 2025, as disclosed in the Prospectus Supplement filed with the SEC on June 25, 2025.


SCHEDULE 13G



 
Ikarian Capital, LLC
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:08/14/2025
 
Neil Shahrestani
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:08/14/2025

Comments accompanying signature:  A Joint Filing Agreement is incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on February 14, 2025 by the Reporting Persons with the SEC.